RichardAlanBenderMDFACP

PubMed

• 43 citations
  Molecular Classification of Unknown Primary Cancer
  Richard A. Bender, Mark G. Erlander
  Seminars in Oncology. 2009-02-01
• 84 citations
  The pharmacokinetics of [3H]-vincristine in man
  Richard A. Bender, Manford C. Castle, David A. Margileth, Vincent T. Oliverio
  Clinical Pharmacology and Therapeutics. 1977-10-01
• 186 citations
  The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
  Xiao-Jun Ma, Susan G. Hilsenbeck, Wilson Wang, Li Ding, Dennis C. Sgroi
  Journal of Clinical Oncology. 2006-10-01

Journal Articles

• "Molecular Identification of Carcinoma of Unknown Primary (CUP) with Gene Expression Profiling"  
  Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
• "Preliminary Study of Three Tumor Markers for Hepatocellular Carcinoma: AFP, AFP-L3 and Glypican-3"  
  Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
• "A Multiplex Assay for Detection of Common Pediatric Sarcoma Tumor Markers"  
  Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
• "Clinical Validation of a Self-Organizing Map (SOM) Based Quantitative Prediction Algorithm for Diagnosis of Cancer of Unknown Primary (CUP)"  
  Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
• Join now to see all

Abstracts/Posters

• Personalized Treatment of Advanced Metastatic Breast Cancer (MBC) Utilizing Target Now in a Community- Based Oncology Practice
  Loesch D, Waisman J, Link J, Alarcon A, Boehm K, Ghazadpour A and Bender R,, San Antonio Breast Cancer Symposium, 12/7/2011
• Differences in gene expression between primary chemotherapy-naïve prostate carcinomas and hormone-refractory prostate carcinomas
  Basu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference, San Francisco, 11/16/2011
• Differences in gene expression between primary chemotherapy-naive prostate carcinomas and hormone-refractory prostate carcinomas
  Basu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference on “Molecular Targets and Cancer Therapeutics", 11/12/2011
• "Differences in gene expression between primary chemotherapy-naïve prostate carcinomas and hormone-refractory prostate carcinomas"
  Basu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference on "Molecular Targets and CancerTherapeutics", San Francisco, 11/12/2011
• Immunohistochemical Biomarker assessment of Stage III Colon Cancer undergoing Sentinel lymph node mapping using “Caris Target Now
  Saha S, Wiese D, Kanaan M, Loesch D, Ashfaq R, Alarcon A, Gerkin R and Bender R, Society of Surgical Oncology, 9/2011
• Immunohistochemical Biomarker assessment of Stage III Colon Cancer undergoing Sentinel lymph node mapping using “Caris Target Now” on overall survival and recurrence
  Saha S, Wiese D, Kanaan M, Loesch D, Ashfaq R, Alarcon A, Gerkin R and Bender R, Society of Surgical Oncology, 9/1/2011
• Personalized Treatment of Advanced Metastatic Breast Cancer (MBC) Utilizing Target Now in a Community- Based Oncology Practice
  Loesch D, Waisman J, Link J, Alarcon A, Boehm K, Ghazadpour A and Bender R, San Antonio Breast Cancer Symposium, San Antonio, TX, 7/10/2011
• "Gene Expression Profiling for Prognosis and Prediction in Early Stage Breast Cancer"
  Richard A. Bender, MD, Tumor Boards, Multiple locations, 6/1/2009
• The 70-Gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer.
  Knauer M, Straver M , Rutgers E, Bender RA et. al., The Breast, St Gallen International Conference on Primary Therapy of Early Breast Cancer, 3/1/2009
• Early Prognosis Prediction: MammaPrint on core-needle biopsies.
  DeSnoo F, Glas A and Bender RA, The Breast, St Gallen International Conference on Primary Therapy of Early Breast Cancer, 3/1/2009
• Early Prognosis Prediction: MammaPrint on core-needle biopsies
  DeSnoo F, Glas A and Bender RA, St Gallen international conference, 3/2009
• The 70-Gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer.
  Knauer M, Straver M , Rutgers E, Bender RA, St Gallen international conference, 3/2009
• Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments.
  Roepman P, Horlings H, Krijgsman O, Bueno-de-Mesquita J, Bender RA et. al., Cancer Res, San Antonio Breast Cancer Symposium, 1/1/2009
• Gene Expression Profiling for Prognosis and Prediction in Early Stage Breast Cancer
  Bender RA, Tumor Boards at UCLA-Harbor General Hospital, Stanford University, Loma Linda Medical Center, NYU Medical Center and Portland Medical Center, 1/1/2009
• Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments
  Roepman P, Horlings H, Krijgsman O, Bueno-de-Mesquita J, Bender RA et. Al, Cancer Res and San Antonio Breast Cancer Symposium, 1/1/2009
• The 70-Gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer
  Knauer M, Straver M , Rutgers E, Bender RA et. Al, The Breast and St Gallen international conference on primary therapy of early breast cancer, 1/1/2009
• Early Prognosis Prediction: MammaPrint on core-needle biopsies
  DeSnoo F, Glas A and Bender RA, The Breast and St Gallen international conference on primary therapy of early breast cancer, 1/1/2009
• Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments
  Roepman P, Horlings H, Krijgsman O, Bueno-de-Mesquita J, Bender RA, San Antonio Breast Cancer Symposium, 12/2008
• Human epididymis secretory protein in serum (HE4) as a marker of ovarian cancer
  Li H, Qu KZ, Sferruza AD, Whitmire R and Bender RA, 2008 meeting of the American Society of Clinical Oncology, 6/1/2008
• Utility of four tumor markers alone and in combination for detection of Hepatocellular Carcinoma: AFP, AFP-L3, DCP and Cystatin C
  Li H, Sferruza AD, Qu KZ, Afdahl NH, Radcliff JS and Bender RA, 2008 meeting of the American Society of Clinical Oncology, 6/1/2008
• Human epididymis secretory protein in serum (HE4) as a marker of ovarian cancer.
  Li H, Qu KZ, Sferruza AD , Whitmire R and Bender RA, Meeting of the American Society of Clinical Oncology, Chicago, 6/1/2008
• Utility of four tumor markers alone and in combination for detection of Hepatocellular Carcinoma: AFP, AFP-L3, DCP and Cystatin C.
  Li H, Sferruza AD, Qu KZ, Afdahl NH, Radcliff JS and Bender RA, Meeting of the American Society of Clinical Oncology, Chicago, 6/1/2008
• Using Gene Expression Assays to Guide Therapy in Breast Cancer
  Bender RA, American Association for Clinical Chemistry (AACC), 11/1/2007
• "Using Gene Expression Assays to Guide Therapy in Breast Cancer"
  Richard A. Bender, MD, American Association for Clinical Chemistry (AACC) Meeting, St. Louis, MO, 11/1/2007
• "A Sensitive Method for Detection of EGFR Gene Mutations in Plasma"
  Richard A. Bender, MD, American Society of Clinical Oncology Meeting, Chicago, 6/3/2007
• Join now to see all